These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 18484780)
1. Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial. Ruland S Drug Saf; 2008; 31(6):449-58. PubMed ID: 18484780 [TBL] [Abstract][Full Text] [Related]
2. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. Jamieson DG; Parekh A; Ezekowitz MD J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203 [TBL] [Abstract][Full Text] [Related]
4. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists. Fintel DJ Clin Cardiol; 2007 Dec; 30(12):604-14. PubMed ID: 17847044 [TBL] [Abstract][Full Text] [Related]
6. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected]. Kirshner HS Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660 [TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines. Hankey GJ Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741 [TBL] [Abstract][Full Text] [Related]
8. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Squizzato A; Bellesini M; Takeda A; Middeldorp S; Donadini MP Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005158. PubMed ID: 29240976 [TBL] [Abstract][Full Text] [Related]
9. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153 [TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741 [TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876 [TBL] [Abstract][Full Text] [Related]
12. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis. Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347 [TBL] [Abstract][Full Text] [Related]
13. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Hacke W Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184 [TBL] [Abstract][Full Text] [Related]
14. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Squizzato A; Keller T; Romualdi E; Middeldorp S Cochrane Database Syst Rev; 2011 Jan; (1):CD005158. PubMed ID: 21249668 [TBL] [Abstract][Full Text] [Related]
15. MATCH results: implications for the internist. Lutsep HL Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967 [TBL] [Abstract][Full Text] [Related]
16. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Hankey GJ; Johnston SC; Easton JD; Hacke W; Mas JL; Brennan D; Mak KH; Bhatt DL; Fox KA; Topol EJ; Int J Stroke; 2011 Feb; 6(1):3-9. PubMed ID: 21205234 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. Malloy RJ; Kanaan AO; Silva MA; Donovan JL Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421 [TBL] [Abstract][Full Text] [Related]
18. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Flaherty K; Havard D; Heptinstall S; James M; Krishnan K; Markus HS; Montgomery AA; Pocock SJ; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N; Lancet; 2018 Mar; 391(10123):850-859. PubMed ID: 29274727 [TBL] [Abstract][Full Text] [Related]